{Reference Type}: Journal Article
{Title}: Follicular fluid advanced glycation end products in assisted reproduction: A systematic review.
{Author}: Roushenas F;Hamdi K;Jafarpour F;Fattahi A;Pashaiasl M;Nasr-Esfahani MH;
{Journal}: Clin Chim Acta
{Volume}: 549
{Issue}: 0
{Year}: 2023 Sep 1
{Factor}: 6.314
{DOI}: 10.1016/j.cca.2023.117560
{Abstract}: Follicular fluid (FF) advanced glycation end products (AGEs) have been associated with low oocyte quality and number, low fertilization rate, impaired embryonic development and low pregnancy rate. These findings are especially relevant in women undergoing in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), ie, assisted reproductive technology (ART). A systematic literature search was conducted to examine various AGEs including pentosidine, carboxymethyl-lysine (CML), methylglyoxal 5-hydro-5-methylimidazolones (MG-H1), toxic AGE (TAGE), and soluble receptor for AGE (sRAGE) with ART outcomes. Studies showed that total AGEs and sRAGE in FF were associated with the ovarian response, follicle number, retrieved oocyte number, mature (MII) oocyte number, fertilization rate, embryo number, embryo quality, and successful pregnancy. Although FF AGEs could be considered predictive biomarkers, population heterogeneity and differences in ovulation induction protocols make the findings less clear. This review highlights important role of AGEs in ART and necessity of evaluating AGEs in serum vs with FF to better predict ART outcomes.